Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + dapagliflozin versus insulin glargine in adults with type 2 diabetes inadequately controlled on metformin with or without sulfonylurea
2015-001702-33Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of saxagliptin, dapagliflozin and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in HbA1c at Week 24. Started Oct 2015; status: completed.
02
Drugs
saxagliptindapagliflozininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-001702-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001702-33.